Harry Iland

3.4k total citations · 1 hit paper
61 papers, 1.5k citations indexed

About

Harry Iland is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Harry Iland has authored 61 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 24 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Harry Iland's work include Acute Myeloid Leukemia Research (25 papers), Retinoids in leukemia and cellular processes (14 papers) and Lymphoma Diagnosis and Treatment (9 papers). Harry Iland is often cited by papers focused on Acute Myeloid Leukemia Research (25 papers), Retinoids in leukemia and cellular processes (14 papers) and Lymphoma Diagnosis and Treatment (9 papers). Harry Iland collaborates with scholars based in Australia, United States and Belgium. Harry Iland's co-authors include John László, David S. H. Rosenthal, Seamus Murphy, John Gibson, Alberto Catalano, John F. Seymour, Christina Brown, Derek McCulloch, P. Joy Ho and D. Joshua and has published in prestigious journals such as Blood, International Journal of Molecular Sciences and Clinical Chemistry.

In The Last Decade

Harry Iland

60 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group.

1986 407 citations Harry Iland et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Harry Iland Australia	18	838	591	550	260	161	61	1.5k
Masakazu Nitta Japan	21	566 0.7×	765 1.3×	386 0.7×	277 1.1×	101 0.6×	82	1.5k
Marcel P. Devetten United States	20	704 0.8×	433 0.7×	594 1.1×	263 1.0×	106 0.7×	45	1.5k
Hongyan Tong China	20	764 0.9×	514 0.9×	250 0.5×	225 0.9×	94 0.6×	169	1.3k
Robert Hast Sweden	23	1.4k 1.7×	461 0.8×	587 1.1×	345 1.3×	73 0.5×	99	2.0k
Ming‐Ching Shen Taiwan	23	805 1.0×	490 0.8×	255 0.5×	221 0.8×	52 0.3×	91	1.4k
Michael Pfeilstöcker Austria	22	1.9k 2.3×	594 1.0×	942 1.7×	266 1.0×	64 0.4×	83	2.3k
Angela Michelutti Italy	24	701 0.8×	566 1.0×	315 0.6×	662 2.5×	316 2.0×	62	1.8k
Frances M. Gibson United Kingdom	20	755 0.9×	335 0.6×	314 0.6×	209 0.8×	68 0.4×	56	1.4k
Jin Takeuchi Japan	22	987 1.2×	448 0.8×	344 0.6×	390 1.5×	186 1.2×	94	1.7k
Cristina Arbona Spain	18	630 0.8×	259 0.4×	294 0.5×	269 1.0×	91 0.6×	53	1.3k

Countries citing papers authored by Harry Iland

Since Specialization

Citations

This map shows the geographic impact of Harry Iland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry Iland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry Iland more than expected).

Fields of papers citing papers by Harry Iland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry Iland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry Iland. The network helps show where Harry Iland may publish in the future.

Co-authorship network of co-authors of Harry Iland

This figure shows the co-authorship network connecting the top 25 collaborators of Harry Iland. A scholar is included among the top collaborators of Harry Iland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry Iland. Harry Iland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wei, Andrew H., Harry Iland, Courtney D. DiNardo, & John Reynolds. (2025). Measurable residual disease intervention in AML: a new therapeutic horizon. Blood. 147(1). 13–23.

Epstein‐Peterson, Zachary D., Andriy Derkach, Susan M. Geyer, et al.. (2022). Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Advances. 6(11). 3433–3439. 7 indexed citations

Abadir, Edward, Robin Gasiorowski, Kaitao Lai, et al.. (2019). CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation. Molecular Oncology. 13(10). 2107–2120. 7 indexed citations

McCulloch, Derek, Christina Brown, & Harry Iland. (2017). Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives. OncoTargets and Therapy. Volume 10. 1585–1601. 65 indexed citations

Hocking, Jane S., Anthony P. Schwarer, Robin Gasiorowski, et al.. (2014). Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol. Leukemia & lymphoma. 55(12). 2801–2807. 15 indexed citations

Iland, Harry, John F. Seymour, & Andrew H. Wei. (2013). Optimal approach for high-risk acute promyelocytic leukemia. Current Opinion in Hematology. 21(2). 102–113. 7 indexed citations

Brown, Christina, Stephen Larsen, Harry Iland, D. Joshua, & John Gibson. (2012). Leukaemias into the 21st century: part 1: the acute leukaemias. Internal Medicine Journal. 42(11). 1179–1186. 11 indexed citations

Ling, Silvia, Alberto Catalano, Harry Iland, et al.. (2011). Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica. 97(1). 64–72. 103 indexed citations

Iland, Harry, et al.. (2009). Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin. Australasian Journal of Dermatology. 50(1). 56–59. 24 indexed citations

10.

Iland, Harry, Mark Hertzberg, & Paula Marlton. (2006). Myeloid leukemia : methods and protocols. Humana Press eBooks. 14 indexed citations

11.

Ling, Silvia, Douglas Joshua, John Gibson, et al.. (2006). Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?. American Journal of Hematology. 81(2). 110–114. 11 indexed citations

12.

Applegate, Tanya, Harry Iland, Elisa Mokany, & Alison V. Todd. (2002). Diagnosis and Molecular Monitoring of Acute Promyelocytic Leukemia Using DzyNA Reverse Transcription-PCR to Quantify PML/RARα Fusion Transcripts. Clinical Chemistry. 48(8). 1338–1343. 6 indexed citations

13.

Stevenson, William, et al.. (2002). Disseminated Granulocytic Sarcoma Treated with Allogeneic Peripheral Blood Stem-cell Transplantation. Leukemia & lymphoma. 43(11). 2221–2224. 9 indexed citations

14.

Iland, Harry, et al.. (1999). High-resolution analysis of gene rearrangements in lymphoid malignancies. Pathology. 31(3). 252–256. 12 indexed citations

15.

Dunkley, Scott, et al.. (1999). Acute Promyelocytic Leukaemia Complicating Multiple Myeloma: Evidence of Different Cell Lineages. Leukemia & lymphoma. 35(5-6). 623–626. 4 indexed citations

16.

Todd, Alison V. & Harry Iland. (1991). Rapid Screening of Mutant N-ras Alleles by Analysis of PCR-Induced Restriction Sites: Allele Specific Restriction Analysis (ASRA). Leukemia & lymphoma. 3(4). 293–300. 14 indexed citations

17.

Todd, Alison V., et al.. (1991). Analysis of N‐ras gene mutations in acute myeloid leukemia by allele specific restriction analysis. American Journal of Hematology. 38(3). 207–213. 13 indexed citations

18.

Young, Graham, et al.. (1991). Late Relapses in Hodgkin's Disease: Are They a Distinct Entity?. Leukemia & lymphoma. 4(5-6). 363–369. 1 indexed citations

19.

Gibson, John, D. Joshua, G. A. R. Young, et al.. (1989). A RANDOMISED TRIAL OF EMPIRICAL ANTIBIOTIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH HEMATOLOGICAL DISORDERS: CEFTAZIDIME VERSUS AZLOCILLIN PLUS AMIKACIN. Australian and New Zealand Journal of Medicine. 19(5). 417–425. 13 indexed citations

20.

Young, G. A. R., et al.. (1984). Steroid responsive cyclical neutropenia. Annals of Hematology. 48(3). 153–159. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact